|Class Period:||Jun-16-13 to Mar-11-14|
|Lead Plaintiff Deadline:||May-16-14|
GERN is a clinical stage company with only one drug in development - imetelstat - which is in Phase 2 trials. The Complaint alleges that between June 16, 2013, and March 11, 2014, Geron omitted to disclose material facts showing imetelstat's poor prospects, including that (1) persistent low-grade liver function test (LFT) abnormalities had been observed in the Phase 2 study of imetelstat in essential thrombocythemia (ET) or polycythemia vera (PV) patients and (2) there was a potential risk of chronic liver injury following long-term exposure to imetelstat.
On March 12, 2014, GERN announced that the Food and Drug Administration had verbally informed it that a clinical hold would be placed on imetelstat clinical trials, citing the LFT abnormalities and the potential risk of chronic liver injury. The FDA additionally is concerned that both may be irreversible.
That day, GERN's stock price fell $2.71, or 62%, on heavy volume, damaging investors.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.